TNF-α promoter region gene polymorphisms in HIV-positive patients with lipodystrophy
- 1 October 2002
- journal article
- Published by Wolters Kluwer Health in AIDS
- Vol. 16 (15) , 2013-2018
- https://doi.org/10.1097/00002030-200210180-00005
Abstract
The pathogenic mechanisms underlying lipodystrophy in HIV-positive patients are largely unknown. TNF-alpha has many actions that are consistent with the features of lipodystrophy; therefore, an analysis was carried out to determine whether functionally active polymorphisms in the promoter region of the TNF-alpha gene are associated with the development of lipodystrophy. Genetic case-control association study. Individuals were genotyped for the -238 and -308 polymorphisms in the TNF-alpha gene using polymerase chain reaction-restriction fragment length polymorphism analysis. The genotype and allele frequencies for 61 HIV-positive patients with lipodystrophy were compared with (a) 35 HIV-positive patients with no evidence of lipodystrophy and (b) 239 healthy HIV-negative individuals. The frequency of the variant rare -238 allele was significantly different (P = 0.01) in HIV-positive patients with lipodystrophy than in those without lipodystrophy. At the genotype level, a trend towards a difference between patients with and without lipodystrophy was observed (chi2 for linear trend 5.2, P = 0.02). For the -308 polymorphism, no difference was found in genotype and allele frequencies between HIV patients with and without lipodystrophy. The data suggest that the -238 (but not the -308) promoter region TNF-alpha gene polymorphism is a determinant in the development of HIV-related lipodystrophy. However, the results need to be confirmed in larger numbers of patients as well as in an ethnically diverse population.Keywords
This publication has 36 references indexed in Scilit:
- Pushing the envelope on lipodystrophyNature Genetics, 2000
- Toxicity of Antiretroviral Nucleoside and Nucleotide AnaloguesDrug Safety, 2000
- Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophyThe Lancet, 1999
- Host Genetics of Infectious Diseases: Old and New Approaches ConvergeEmerging Infectious Diseases, 1998
- Fat accumulation and HIV-1 protease inhibitorsThe Lancet, 1998
- Pseudo‐Cushing's Syndrome in Human Immunodeficiency Virus– Infected PatientsClinical Infectious Diseases, 1998
- Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistanceThe Lancet, 1998
- TNF-α promoter polymorphisms, production and susceptibility to multiple sclerosis in different groups of patientsJournal of Neuroimmunology, 1997
- An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles.The Journal of Experimental Medicine, 1993
- Endotoxin‐Stimulated Human Monocyte Secretion of Interleukin 1, Tumour Necrosis Factor Alpha, and Prostaglandin E2 Shows Stable Interindividual DifferencesScandinavian Journal of Immunology, 1988